Subscribe
Magazine
Past Issues
Surveys
Industry Statistics
About Us
Members Only
Best Places to Work
General Interest
Exploration & Development
Drilling & Production
Refining & Processing
Pipelines & Transportation
LNG
Energy Transition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
PennEnergy Stock Watch
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Quest Diagnostics
(NY:
DGX
)
146.01
-0.83 (-0.57%)
Official Closing Price
Updated: 7:00 PM EDT, Jul 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Quest Diagnostics
< Previous
1
2
3
4
5
6
7
8
9
Next >
Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy
July 18, 2024
From
Lisata Therapeutics, Inc.; Quest Diagnostics, Haystack Oncology
Via
GlobeNewswire
EXCLUSIVE: Haystack Oncology Inks Research Collaboration With Lisata Therapeutics To Use Haystack MRD Technology To Evaluate Pancreatic Cancer Therapy Efficacy
July 18, 2024
Haystack Oncology, a Quest Diagnostics company, and Lisata Therapeutics collaborate to use Haystack MRD technology in a study of certepetide plus chemotherapy for metastatic pancreatic cancer, focusing...
Via
Benzinga
S&P Global To Rally More Than 13%? Here Are 10 Top Analyst Forecasts For Friday
July 05, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Cracking The Code: Understanding Analyst Reviews For Quest Diagnostics
July 05, 2024
Via
Benzinga
How Is The Market Feeling About Quest Diagnostics?
June 27, 2024
Via
Benzinga
Peering Into Quest Diagnostics's Recent Short Interest
June 10, 2024
Via
Benzinga
Analyst Scoreboard: 7 Ratings For Quest Diagnostics
May 30, 2024
Via
Benzinga
Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests
June 18, 2024
Myriad Genetics Inc. (NASDAQ: MYGN) is a leader in genetic testing and precision medicine. The company offers a wide variety of genetic tests including
Via
MarketBeat
How Is The Market Feeling About Quest Diagnostics?
May 24, 2024
Via
Benzinga
Employers Struggle with Drug Test Policies Amid Varying State Laws, Cheating on Drug Tests Reaches 30-Year High
May 15, 2024
Cheating on drug tests among American workers has reached a 30-year high, with Quest Diagnostics Inc. reporting 31,000 tampered samples out of 5.5 million in 2023. The rise in synthetic urine use and...
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Intelligent Bio Solutions Screening Technologies Poised to Disrupt The Healthcare Sector: INBS, LH, ABT, DGX
April 30, 2024
Via
AB Newswire
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
April 29, 2024
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Peering Into Quest Diagnostics's Recent Short Interest
April 24, 2024
Via
Benzinga
The Analyst Landscape: 5 Takes On Quest Diagnostics
April 24, 2024
Via
Benzinga
Balancing Dividends and Fundamentals: The Case of NYSE:DGX.
April 10, 2024
Uncovering Dividend Opportunities with QUEST DIAGNOSTICS INC (NYSE:DGX).
Via
Chartmill
Intelligent Bio Solutions’ Fingerprint Drug Screening Technology Poised For Massive Growth
April 25, 2024
Intelligent Bio Solutions (Nasdaq: INBS) is a medical technology company developing and commercializing innovative, intelligent, rapid, noninvasive testing solutions.
Via
Talk Markets
Quest Diagnostics Says Sales In Q1 Increased For The First Time Since The Height Of Pandemic
April 23, 2024
Latest financial insights from Quest Diagnostics. Q1 results beat estimates with adjusted EPS of $2.04 and sales of $2.34 billion, showcasing nearly 6% base business revenue growth.
Via
Benzinga
DGX Stock Earnings: Quest Diagnostics Beats EPS, Beats Revenue for Q1 2024
April 23, 2024
DGX stock results show that Quest Diagnostics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
US Stocks Set To Open Fresh Week Higher On Big Tech Earnings Hopes: Analyst Warns Any Letdown Could Push Market 'Deeper Into Oversold Territory'
April 22, 2024
Wall Street appears to be shrugging off rate worries as major stock index futures were moderately higher in early pre-market trading on Monday in the hopes of getting some respite from Big Tech...
Via
Benzinga
Key Takeaways From Quest Diagnostics Analyst Ratings
March 20, 2024
Via
Benzinga
Why NYSE:DGX provides a good dividend, while having solid fundamentals.
March 19, 2024
Balancing Dividends and Fundamentals: The Case of QUEST DIAGNOSTICS INC (NYSE:DGX).
Via
Chartmill
(DGX) - Analyzing Quest Diagnostics's Short Interest
March 05, 2024
Via
Benzinga
Earnings Scheduled For April 23, 2024
April 23, 2024
Companies Reporting Before The Bell • RTX (NYSE:RTX) is expected to report quarterly earnings at $1.23 per share on revenue of $18.41 billion.
Via
Benzinga
Why NYSE:DGX provides a good dividend, while having solid fundamentals.
February 27, 2024
Balancing Dividends and Fundamentals: The Case of QUEST DIAGNOSTICS INC (NYSE:DGX).
Via
Chartmill
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
April 21, 2024
Corporate profit growth rose in Q3 2023 and is expected to continue in Q1.
Via
Benzinga
LifeMD Shares Come Back to Life on GLP-1 Business Growth
March 19, 2024
LifeMD stock is surging as the company is riding the GLP-1 trend to double-digit revenue growth and projections for 67% earnings growth in 2024
Via
MarketBeat
AMC Entertainment Tops The List Of High-Yielding Corporate Bonds — A Look At Yields As Bond Appetites Grow
March 18, 2024
Benzinga used Public.com's bond screener tool to identify some of the highest-yielding investment-grade corporate bonds.
Via
Benzinga
Topics
Bonds
Exposures
Debt Markets
Breaking Down Quest Diagnostics: 7 Analysts Share Their Views
February 26, 2024
Via
Benzinga
Spotify To Rally Around 36%? Here Are 10 Top Analyst Forecasts For Wednesday
February 07, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Is NYSE:DGX suited for dividend investing?
February 05, 2024
Analyzing QUEST DIAGNOSTICS INC (NYSE:DGX)'s Dividend Potential.
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.